T he renin-angiotensin system (RAS) is an important regulator of blood pressure and body fluid homeostasis. The effects of this system are primarily mediated by the multifunctional peptide angiotensin II, which is produced through a series of enzymatic reactions. Circulating angiotensinogen is made in the liver. The protease renin, which is released from the juxtaglomerular apparatus of the kidney, cleaves angiotensinogen to form the decapeptide angiotensin I, which is then further cleaved by angiotensin-converting enzyme (ACE) to form the octapeptide angiotensin II. The many biological effects of angiotensin II are mediated through its interaction with specific cell surface receptors.
In summary, a new family of proteins whose function is consistent with their proposed role as epithelial Cl -channels has recently been identified. These proteins may underlie the Ca 2+ -dependent Cl -secretion observed in some epithelial tissues, but resolution of their function will require a greater understanding of these new potential channels, in particular in terms of their precise cellular location, tissue distribution, and regulatory characteristics. These channels may be appropriate targets for therapeutic intervention in CF. However, mechanisms designed to increase Ca 2+ in the cell are unlikely to be successful; not only can Ca 2+ have deleterious consequences on cell function, but the bCaCC at least is in fact not very sensitive to Ca 2+ in the physiological range in the absence of CaMK II. It will likely be more appropriate to focus on the IP 4 inhibitory pathway or on drugs that could maintain channel P o in the presence of IP 4 and CaMK II. AT 1B expression appears to be more prominent. Angiotensin II regulates blood pressure through its actions as a potent vasoconstrictor, its ability to modulate sodium reabsorption by the kidney, and by stimulating the release of both vasopressin and aldosterone. Angiotensin II stimulates cellular proliferation in a number of cell types, and several studies have identified roles for angiotensin II in growth and development. These classically recognized functions of angiotensin II are primarily mediated by AT 1 receptors.
AT 2 receptors are widely expressed in fetal tissues during late gestation but are also present in adult rodents and humans in discrete locations within the brain, heart, and kidney. The signal transduction pathways of the AT 2 receptor have not been as clearly defined as that of AT 1 receptors. In general, AT 2 receptors appear to have functions opposite (and perhaps balancing) those of AT 1 receptors (6).
The RAS contributes to the pathogenesis of several human diseases, including hypertension, congestive heart failure, coronary artery disease, and diabetic nephropathy. Although the effects of angiotensin II on hemodynamic and cellular function both promote pathology, their relative importance and the specific contributions of individual receptor subtypes to cardiovascular disease is not clear. Thus elucidating the physiological function of angiotensin receptors should provide insights into normal physiology and into the pathogenesis and treatment of common human diseases.
Gene targeting and the RAS
Using homologous recombination in embryonic stem cells, genes can be altered in a specific and targeted fashion. This, in turn, allows the physiologist to examine the effects of altering a single gene product on the homeostasis of an intact animal. Gene targeting has been successfully applied to the study of the RAS, and all of the known genes that encode elements of this system have been disrupted. Because germ-line competent embryonic stem cells have only been isolated from mice, this small mammal is the only species in which gene targeting is currently possible. The body size of the mouse was an initial impediment to physiological experimentation. However, many techniques used in larger species have now been adapted for use in mice. In this review, we will discuss contributions of gene-targeting experiments to understanding the multiple functions of angiotensin receptors.
Angiotensin receptors in growth and development
Several lines of evidence have indicated important roles for angiotensin II in growth and development. RAS gene expression is enhanced in many fetal tissues, and angiotensin receptors are expressed in a tightly regulated pattern during late gestation and in the postnatal period. In rodents and sheep, treatment with ACE inhibitors or AT 1 receptor antagonists, even for a limited time in the neonatal period, results in diminished somatic and kidney growth as well as abnormal kidney structure. The use of ACE inhibitors during pregnancy is also teratogenic to the human fetus and may result in oligohydramnios and neonatal renal failure.
This evidence supporting a role for the RAS in development suggested that dramatic phenotypes would be seen in the mice with targeted disruption of the individual RAS genes. Surprisingly, mice that are unable to synthesize angiotensin II due to targeted disruptions of either the angiotensinogen or ACE genes are born in expected numbers with normal structures of their major organs. However, a significant number of these angiotensin II-deficient mice die during the early postnatal period (1). Moreover, ACE-or angiotensinogen-deficient mice that survive to adulthood have diminished somatic growth and develop a series of structural abnormalities in their kidneys. The kidney pathology consists of medial arterial thickening of interlobular vessels and atrophy of the inner medulla. This vascular pathology is not present in other organs such as heart, adrenal gland, or liver. Because the phenotypes of ACE and angiotensinogen deficiency are virtually identical and the phenotype can be rescued in angiotensinogen-deficient mice by human renin and angiotensinogen transgenes, its pathogenesis seems to be caused by the absence of angiotensin II (2) .
The role of individual angiotensin receptors in the abnormalities caused by angiotensin II deficiency was clarified by analysis of mice with targeted disruption of the AT 1A , AT 1B , and AT 2 receptors. On mixed genetic backgrounds, the phenotype of reduced survival and kidney abnormalities was not recapitulated by the individual targeted disruption of the known angiotensin receptors (1). AT 1A receptor-deficient mice have a minimal survival disadvantage that is evident only after analysis of large numbers of offspring, and they manifest hypertrophied juxtaglomerular apparati. However, they lack the obvious atrophy of the inner medulla seen in angiotensin II-deficient mice. Analysis of large numbers of AT 1A knockouts also failed to demonstrate any deficits in renal, cardiac, or somatic growth. Using careful morphometric analysis, Matsusaka et. al. (9) found that the intrarenal arteries of AT 1A knockouts exhibit mild medial thickening but to a much lesser degree than angiotensin II-deficient mice. The AT 1B -and AT 2 -deficient mice have normal renal morphology and are visually and histomorphologically indistinguishable from their wild-type littermates.
"...angiotensin receptors are expressed in a tightly regulated pattern during late gestation and in the postnatal period."
Because the AT 1A and AT 1B genes are on separate chromosomes, AT 1A receptor-deficient and AT 1B receptor-deficient mice could be crossed, ultimately yielding mice with combined disruption of both AT 1A and AT 1B receptors that are completely deficient of AT 1 receptors (12, 14) . These AT 1 receptor-deficient mice have diminished survival and somatic growth, resembling that seen in angiotensin II-deficient mice. AT 1A /AT 1B double knockout mice also develop the severe kidney phenotype of angiotensin II-deficient mice, as illustrated in Fig. 1 . Thus the lack of either individual AT 1 isoform is compensated for by the remaining receptor in regard to these phenotypes. These studies demonstrate the importance of AT 1 receptors in mediating the effects of angiotensin II in growth and development.
Regulation of blood pressure and sodium balance
The RAS is a potent regulator of sodium and fluid balance. Dysregulation of the RAS causes chronic elevations in blood pressure in experimental models and in patients with hypertension. The efficacy of antagonists of the RAS as antihypertensive agents in large numbers of affected individuals provides compelling evidence for the role of this system in the pathogenesis of hypertension. The Guyton hypothesis proposes that the actions of the RAS in causing hypertension must involve chronic alterations in renal sodium handling (4) .
The role of the RAS in modulating sodium excretion by the kidney has been well documented. For example, in animal models and in humans, suppression of angiotensin II production is required for normal excretion of a sodium load, whereas chronic administration of subpressor doses of angiotensin II increases blood pressure by altering sodium balance (5) . Conversely, during sodium depletion, pharmacological inhibition of the RAS causes an inappropriate natriuresis and reductions in blood pressure. Angiotensin II may affect sodium excretion through several discrete mechanisms, including: 1) effects on renal hemodynamics, 2) direct stimulation of renal tubular sodium reabsorption, and 3) stimulation of aldosterone production by the adrenal glands.
The severe structural abnormalities of the angiotensin IIdeficient models (angiotensinogen or ACE knockout mice) limit their usefulness in the study of the physiological actions of angiotensin II in the kidney. Because kidney structure is normal in mice with targeted deletion of either AT 1A or AT 1B or of AT 2 receptors, these lines of mice are ideal models to study the roles of angiotensin II in the regulation of blood pressure and sodium balance.
AT 1 receptors. Targeted disruption of the angiotensinogen, ACE, or AT 1A receptor genes decreases blood pressure (1). The magnitude of blood pressure reduction, measured directly by intra-arterial catheters or indirectly using tail-cuff manometry, is similar in these three lines of knockout mice and is ~25-30 mmHg. Additionally, a more subtle alteration of angiotensinogen or AT 1A receptor expression in mice heterozygous for the respective gene disruptions causes a modest but significant reduction of blood pressure, as shown in Fig. 2 (8) . This indicates that mutations causing quantitative alterations in expression of these genes may have significant effects on resting blood pressure. In contrast, AT 1B receptor-deficient mice do not exhibit any reduction in blood pressure or any discernible phenotype. Therefore, targeted disruption of the AT 1B receptor gene did not initially clarify its function. However, AT 1A -deficient (Agtr1a-/-) mice provided direct evidence for actions of AT 1B receptors in blood pressure regulation (1) . AT 1A receptordeficient mice exhibit a modest pressor response to angiotensin II that is blocked by AT 1 receptor antagonists but not by sympatholytic agents, suggesting direct vasoconstrictor actions of AT 1B receptors. In addition, chronic treatment of AT 1A receptor-deficient mice with an AT 1 -specific antagonist causes a further reduction in their systolic blood pressures, suggesting a role for AT 1B receptors in the regulation of blood pressure when AT 1A receptors are absent. Furthermore, AT 1A /AT 1B receptor double knockout mice have no detectable pressor response to angiotensin II (12, 14) . These findings confirm the actions of AT 1B receptor in producing vasoconstriction and argue strongly against the presence of other angiotensin receptors with acute vasoactive effects.
AT 2 receptors. The vasoconstrictor actions of angiotensin II are augmented in AT 2 knockout mice, and at least one of the lines of mice has elevated blood pressure (6) . These studies of AT 2 receptor-deficient mice are consistent with other accumulating evidence suggesting that AT 2 receptors act to negatively modulate the actions of AT 1 receptors to raise blood pressure. Our experiments using AT 1A /AT 1B receptor-deficient mice also support this view (12) . We found that treatment of wild-type mice with an ACE inhibitor causes a substantial reduction in blood pressure. In contrast, ACE inhibition causes a paradoxical increase in the blood pressure of AT 1A /AT 1B double knockouts. We speculate that this effect represents inhibition of AT 2 receptor signaling. Furthermore, the absence of an acute vasodepressor response to angiotensin II infusions in the AT 1A /AT 1B double knockouts suggests that the effect of AT 2 receptors in regulating blood pressure is related to modulation of renal sodium handling rather than direct vascular actions (12, 14) . Recent experiments by Siragy et al. (13) suggest that the negative modulating actions of AT 2 receptors may play a role in the pathogenesis of hypertension. These investigators found that AT 2 receptor-deficient mice develop significant hypertension and reductions in sodium excretion during chronic infusion of low doses of angiotensin II that did not alter blood pressures in wild-type controls. The AT 2 knockout mice had low basal levels of bradykinin and cGMP in renal interstitial fluid, indicating reduced nitric oxide production in the kidney. In wild-type mice, sodium restriction or angiotensin II infusion increased levels of bradykinin and cGMP in renal interstitial fluid; however, this response was absent in AT 2 knockout mice. Thus, although the mechanism of regulation of blood pressure by the AT 2 receptor remains to be clarified, available data suggests that the AT 2 receptor modulates renal sodium handling, possibly through effects on nitric oxide production.
Angiotensin receptors and water balance
The RAS also regulates water metabolism. In the brain, angiotensin II stimulates thirst and can regulate vasopressin (antidiuretic hormone) release. Angiotensin II may also affect water handling in the kidney through its ability to regulate proximal nephron reabsorption of water and solute and by regulating blood flow in the inner medulla. Additionally, AT 1 receptors are expressed in the thick ascending limb of Henle's loop and in collecting ducts, sites that play crucial roles in urinary concentration.
Both angiotensin II-deficient and AT 1A /AT 1B double knockout mice have defects in their ability to concentrate urine in response to thirsting (12) . Given the atrophy of the renal inner medulla seen in these models, this finding was not completely unexpected. Miyazaki et al. (10) have demonstrated arrested development and diminished peristalsis of the renal pelvis in AT 1A /AT 1B double knockout mice. It was hypothesized that this abnormality causes an obstructive nephropathy with subsequent atrophy of the inner medulla of the kidney. However, AT 1A receptor-deficient mice (12) that lack the severe atrophy of the inner medulla of AT 1A /AT 1B double knockouts and ACE-or angiotensin-deficient mice also have significant defects of urine concentration (Fig. 3) . The same conclusion applies to mice that lack only the tissue-bound form of ACE (3). The defect in urinary concentration in AT 1A knockout mice seems to be caused by a kidney defect since their vasopressin responses to thirsting are normal. Furthermore, a urineconcentrating defect is induced in wild-type mice after brief treatment with an AT 1 receptor antagonist (11) . Together, these findings demonstrate a physiological role for AT 1A receptors in the regulation of water handling by the kidney.
Mice lacking AT 2 receptors do not have overt abnormalities in urinary-concentrating function or in maintaining water balance. However, after a period of water deprivation their drinking response is blunted (7) . Because exploratory behavior is globally diminished in AT 2 knockout mice, the relative role of this behavioral abnormality and direct effects of the AT 2 receptor on thirst mechanisms is not yet clear.
Conclusions
The study of AT 1 receptor-deficient mice has reaffirmed and extended our understanding of the roles of AT 1 receptors in regulating growth, development, blood pressure, and circulating volume. Gene-targeting experiments have also provided insights into novel functions of AT 2 receptors.
